Bristol-Myers Squibb (BMY) said Monday that its phase 3 Odyssey-HCM trial, which evaluated Camzyos in adults with symptomatic New York Heart Association class II-III non-obstructive hypertrophic cardiomyopathy, did not meet its dual primary endpoints.
The trial failed to show a statistically significant difference from placebo in changes from baseline to week 48 in both the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score and peak oxygen consumption.
No new safety signals were observed, the company added.
Shares of Bristol-Myers Squibb were down 2% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。